A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma
Qaiser Bashir,Peter F. Thall,Dawen Sui,Jeremy L. Ramdial,Samer A. Srour,Rohtesh S. Mehta,Uday R. Popat,Yago Nieto,Neeraj Saini,Partow Kebriaei,Elisabet E. Manasanch,Hans C. Lee,Gregory P. Kaufman,Sheeba K Thomas,Krina K. Patel,Robert Z. Orlowski,Cristina G. Knape,Jitesh D. Kawedia,Richard E. Champlin,Elizabeth J. Shpall,Xiaoqian Liu,Muzaffar H. Qazilbash
DOI: https://doi.org/10.1182/blood-2021-149807
IF: 20.3
2021-11-05
Blood
Abstract:Abstract Introduction: The most commonly used conditioning regimen for autologous hematopoietic cell transplantation (auto-HCT) in multiple myeloma (MM) is high-dose melphalan. However, conventional melphalan formulations can put patients at risk of potential propylene glycol (PG)-associated toxicities. In addition, the traditional melphalan formulations are unstable at room temperature, which prevents studying longer infusion schedules. The higher stability and potentially lower toxicity of PG-free (PGF) melphalan (Evomela) supports the evaluation of different doses and prolonged infusion schedules, in addition to the traditional 30-60 minute bolus doses. Here, we report interim results of a trial designed to assess whether the characteristics of PGF melphalan allow for a higher dose or prolongation of infusion time, in order to increase the efficacy of melphalan in myeloma patients undergoing auto-HCT. Methods: The primary objective of this two-stage phase I-II trial is to evaluate the optimal dose and schedule of PGF melphalan given as a single agent preparative regimen on day -2 before auto-HCT. The study enrolls adults with non-relapsed MM, a Karnofsky performance score ≥70%, who have received ≥2 cycles of initial systemic therapy and were within 2 to 12 months of their first induction. Participants are randomized (1:1) to two different infusion schedules (30-60 minute or 8-9 hour) using Evomela (2mg/ml) at one of two doses (200 or 225 mg/m 2). The first 3 patients in each schedule were treated at the dose of 200 mg/m 2. Since no DLT was observed, the dose was escalated to 225 mg/m 2. All patients will continue to receive 225 mg/m 2 in the absence of DLT. Disease response was assessed according to the International Myeloma Working Group uniform response criteria. Minimal residual disease (MRD) was measured by using multiparametric flow cytometry (10 -5) in the bone marrow at day-90 after transplant. Secondary outcomes include incidence of treatment related mortality, rate of MRD, complete response at 90 days post auto-HCT, and progression-free and overall survival. Results: To date (July 20,2021), 24 eligible patients have been randomized. Seventeen patients (47% female, mean age 59) are eligible for assessing response 90 days post-treatment, 11 (64.7%) in schedule 1 (30-60 mins) and 6 (35.3%) in schedule 2 (8-9 hrs). The overall response rate (partial response [PR] or better) is 100%, with 5(29.4%) stringent complete remissions (sCR), 5 (29.4%) complete remissions (CR), 4(23.5%) very good partial responses (VGPR), and 3(17.6%) partial remission (PR). The CR+sCR rate is 58.8%. Of the 15 patients eligible for MRD assessment, 11 (73.3%) in schedule 1 and 4 (26.7%) in schedule 2, 11/15 (73.3%) were MRD-negative and 8/15 (53.3%) were sCR/CR+MRD-negative 90 days post-treatment. The median follow-up is 11 months (95%CI:6.1-15.4) No patient has experienced disease progression or death. Dose-limiting toxicity (DLT) is defined as grade 4 mucositis, or any grade 4 or 5 non-hematologic or non-infectious toxicity occurring within 30 days from the start of infusion. Twenty-one patients were evaluable for toxicity monitoring and no patient experienced >grade 3 adverse events with either schedule. Notably, no patient experienced ≥grade 3 esophagitis or oral mucositis. Diarrhea was the most frequent adverse event, and the incidence of grade 3 diarrhea was 18% in the short infusion arm and 43% with the longer infusion. No DLTs have been observed. On pharmacokinetics analysis, the C max was highest in the short infusion arm (p<0.001). The area under the curve (AUC) 0-∞, including the dose-normalized AUC 0-∞ was lower in the short infusion arm; however, the differences were not statistically significant (p=0.815 and p=0.940, respectively). Conclusions: Preliminary trial results have demonstrated that PGF melphalan, as a high-dose conditioning regimen for auto-HCT in patients with MM, has an acceptable safety profile (no >grade 3 events). The response rates, including the CR+MRD-negative rates are encouraging. The impact of bolus versus longer infusion schedule on outcomes will be assessed after the completion of the trial. Figure 1 Figure 1. Disclosures Mehta: Kadmon: Research Funding; CSLBehring: Research Funding; Syndax: Research Funding; Incyte: Research Funding. Popat: Bayer: Research Funding; Abbvie: Research Funding; Novartis: Research Funding; Incyte: Research Funding. Lee: Genentech: Consultancy; Legend Biotech: Consultancy; GlaxoSmithKline: Consultancy, Research Funding; Sanofi: Consultancy; Takeda Pharmaceuticals: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Regeneron: Research Funding; Bristol Myers Squibb: Consultancy; Oncopetides: Consultancy; Karyopharm: Consultancy; Janssen: Consultancy, Research Funding; Celgene: Consultancy. Thomas: Acerta Pharma: Research Funding; Ascentage Pharma: Research Funding; BMS: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; X4 Pharma: Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding. Patel: Pfizer: Consultancy; Janssen: Consultancy, Research Funding; BMS Celgene: Consultancy, Research Funding; Oncopeptides: Consultancy. Orlowski: Amgen, Inc., BioTheryX, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Genzyme, GSK Biologicals, Janssen Biotech, Karyopharm Therapeutics, Inc., Neoleukin Corporation, Oncopeptides AB, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, and Takeda P: Consultancy, Honoraria; CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc.: Other: Clinical research funding; Asylia Therapeutics, Inc., BioTheryX, Inc., and Heidelberg Pharma, AG.: Other: Laboratory research funding; Asylia Therapeutics, Inc.: Current holder of individual stocks in a privately-held company, Patents & Royalties; Amgen, Inc., BioTheryX, Inc., Bristol-Myers Squibb, Celgene, Forma Therapeutics, Genzyme, GSK Biologicals, Janssen Biotech, Juno Therapeutics, Karyopharm Therapeutics, Inc., Kite Pharma, Neoleukin Corporation, Oncopeptides AB, Regeneron Pharmaceuticals, I: Membership on an entity's Board of Directors or advisory committees. Shpall: Takeda: Patents & Royalties; Affimed: Patents & Royalties; Adaptimmune: Consultancy; Magenta: Consultancy; Novartis: Consultancy; Bayer HealthCare Pharmaceuticals: Honoraria; Axio: Consultancy; Navan: Consultancy; Novartis: Honoraria; Magenta: Honoraria. Qazilbash: Bristol-Myers Squibb: Other: Advisory Board; Amgen: Research Funding; Oncopeptides: Other: Advisory Board; Angiocrine: Research Funding; NexImmune: Research Funding; Janssen: Research Funding; Biolline: Research Funding.
hematology